| Assay ID | Title | Year | Journal | Article |
|---|
| AID1240792 | Plasma protein binding in rat | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240807 | Negative allosteric modulation at mGlu8 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240821 | Antianxiolytic activity in po dosed CD1 mouse assessed as inhibition of marble burying behavior | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240808 | Ex vivo occupancy at mGlu5 receptor in po dosed Sprague-Dawley rat assessed as inhibition of [3H]-M-MPEP binding measured after 1 hr post dose by autoradiography | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240805 | Negative allosteric modulation at mGlu6 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240774 | Half life in rat at 8 mg/kg, po | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240819 | Toxicity in Sprague-Dawley rat assessed as gross pathology up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240788 | Apparent permeability across apical to basolateral side of human Caco2 cells | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240814 | Toxicity in Sprague-Dawley rat assessed as hematology up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240789 | Efflux ratio of permeability across human Caco2 cells | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240815 | Toxicity in Sprague-Dawley rat assessed as coagulation up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240804 | Negative allosteric modulation at mGlu4 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240765 | Ratio of drug level in rat cerebrospinal fluid to plasma at 0.5 mg/kg, iv after 2 hrs | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1524387 | Inhibition of mGLU5 (unknown origin) | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes. |
| AID1240777 | AUC (infinity) in rat at 8 mg/kg, po | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240794 | Cytotoxicity against human HepG2 cells assessed as cell viability | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240793 | Metabolic stability in rat plasma assessed as compound remaining after 60 mins | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240766 | Oral bioavailability in rat | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240791 | Plasma protein binding in dog | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240818 | Toxicity in Sprague-Dawley rat assessed as organ weights up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240786 | Inhibition of CYP1A2 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240803 | Negative allosteric modulation at mGlu2 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240798 | Genotoxicity in human TK6 cells in presence of liver S9 fraction | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240801 | Negative allosteric modulation at mGlu3 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240784 | Inhibition of CYP2C8 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240809 | Toxicity in Sprague-Dawley rat assessed as tolerance to dose up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240763 | Ratio of drug level in rat brain to plasma at 0.5 mg/kg, iv after 2 hrs | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240770 | Clearance in rat at 1 mg/kg, iv | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240781 | Inhibition of CYP3A4 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240813 | Toxicity in Sprague-Dawley rat assessed as food consumption up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240797 | Genotoxicity in Salmonella typhimurium by Ames test in absence of liver S9 fraction | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240780 | Oral bioavailability in rat at 8 mg/kg | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240812 | Toxicity in Sprague-Dawley rat assessed as differences in body weight up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240758 | Half life in rat liver microsomes | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240802 | Negative allosteric modulation at mGlu1 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240810 | Toxicity in Sprague-Dawley rat assessed as target organ effects up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240799 | Genotoxicity in human TK6 cells in absence of liver S9 fraction | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240783 | Inhibition of CYP2D6 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240768 | Oral bioavailability in rat at 2 mg/kg | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240787 | Inhibition of human ERG | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240820 | Toxicity in Sprague-Dawley rat assessed as histopathological findings up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240756 | Displacement of [3H]-M-MPEP from human mGlu5 receptor expressed in HEK293 cells after 90 mins by scintillation spectroscopy analysis | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240817 | Toxicity in Sprague-Dawley rat assessed as urinalysis up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240811 | Toxicity in Sprague-Dawley rat assessed as clinical observations up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240782 | Inhibition of CYP2C19 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240796 | Genotoxicity in Salmonella typhimurium by Ames test in presence of liver S9 fraction | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240800 | Negative allosteric modulation at human mGlu5 receptor expressed in HEK293 cells assessed as inhibition of L-quisqualic acid-induced inositol phosphate turnover at 10 uM preincubated for 45 mins before L-quisqualic acid challenge measured after 15 mins by | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240760 | Volume of distribution at steady state in rat at 0.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240757 | Negative allosteric modulation at human mGlu5 receptor expressed in HEK293 cells assessed as inhibition of L-quisqualic acid-induced inositol phosphate turnover preincubated for 45 mins before L-quisqualic acid challenge measured after 15 mins by IPone as | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240762 | Ratio of drug level in rat brain to plasma at 0.5 mg/kg, iv after 0.5 hrs | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240785 | Inhibition of CYP2C9 (unknown origin) | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240806 | Negative allosteric modulation at mGlu7 receptor (unknown origin) at 10 uM | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240759 | Clearance in rat at 0.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240771 | Volume of distribution at steady state in rat at 1 mg/kg, iv | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240816 | Toxicity in Sprague-Dawley rat assessed as clinical chemistry up to 30 mg/kg, po administered as non-GLP 7-day repeat dose | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240769 | Half life in rat at 2 mg/kg, po | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240761 | Half life in rat at 0.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240795 | Fraction unbound in rat brain assessed as equilibrium dialysis between buffer and brain homogenate | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240767 | Half life in po dosed rat | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240790 | Plasma protein binding in human | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1240764 | Ratio of drug level in rat cerebrospinal fluid to plasma at 0.5 mg/kg, iv after 0.5 hrs | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |